Replies to post #249301 on Biotech Values

[WorstLuck]

FWIW a comment from a Nephrologist

Having hard time believing, as a kidney doctor, that the data from Ozempic will have such an impact on CKD patients to the level dialysis stocks have reacted. While I believe it will delay CKD progression, a la gliflozin family, I doubt it will be curative. $DVA $NVO $LLY ...

— Ralph (@StuckInStock) October 11, 2023